<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vmireaviz</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-762X</issn><issn pub-type="epub">2782-1579</issn><publisher><publisher-name>РЕАВИЗ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/vmi-rvz.2026.3.CASE.2</article-id><article-id custom-type="elpub" pub-id-type="custom">vmireaviz-1647</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клинический случай</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical case</subject></subj-group></article-categories><title-group><article-title>Кардиоваскулярная токсичность гипотонического типа после высокодозной химиотерапии с поддержкой собственными стволовыми клетками: описание клинических случаев</article-title><trans-title-group xml:lang="en"><trans-title>Hypotensive cardiovascular toxicity after high-dose chemotherapy with autologous stem cell support: a case series</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-0359-3719</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подсевалов</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Podsevalov</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Подсевалов Владимир Святославович - Очный аспирант кафедры госпитальной терапии с курсами гематологии и трансфузиологии</p><p>ул. Чапаевская, д. 89, г. Самара, 443099, Россия</p></bio><bio xml:lang="en"><p>Vladimir S. Podsevalov - Full-time postgraduate student, Department of Hospital Therapy with Courses in Hematology and Transfusiology</p><p>Chapaevskaya St., 89, Samara, 443099, Russia</p></bio><email xlink:type="simple">v.s.podsevalov@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7133-1689</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гиматдинова</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gimatdinova</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гиматдинова Гелия Рифкатовна - Канд. мед. наук, ассистент кафедры госпитальной терапии с курсами гематологии и трансфузиологии</p><p>ул. Чапаевская, д. 89, г. Самара, 443099, Россия</p></bio><bio xml:lang="en"><p>Geliya R. Gimatdinova - Cand. Sci. (Med.), Assistant Professor, Department of Hospital Therapy with Courses in Hematology and Transfusiology</p><p>Chapaevskaya St., 89, Samara, 443099, Russia</p></bio><email xlink:type="simple">g.r.gimatdinova@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0645-7645</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдкин</surname><given-names>И. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydkin</surname><given-names>I. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Давыдкин Игорь Леонидович - Д-р мед. наук, профессор, заведующий кафедрой госпитальной терапии с курсами гематологии и трансфузиологии</p><p>ул. Чапаевская, д. 89, г. Самара, 443099, Россия</p></bio><bio xml:lang="en"><p>Igor' L. Davydkin - Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy with Courses in Hematology and Transfusiology</p><p>Chapaevskaya St., 89, Samara, 443099, Russia</p></bio><email xlink:type="simple">i.l.davydkin@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4322-0447</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Данилова</surname><given-names>О. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Danilova</surname><given-names>O. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Данилова Олеся Евгеньевна - Канд. мед. наук, доцент кафедры госпитальной терапии с курсами гематологии и трансфузиологии</p><p>ул. Чапаевская, д. 89, г. Самара, 443099, Россия</p></bio><bio xml:lang="en"><p>Olesya E. Danilova - Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy with Courses in Hematology and Transfusiology</p><p>Chapaevskaya St., 89, Samara, 443099, Russia</p></bio><email xlink:type="simple">o.e.danilova@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9041-4885</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетникова</surname><given-names>Ю. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetnikova</surname><given-names>Yu. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Решетникова Юлия Борисовна - Заведующая лабораторией кардиовизуализации</p><p>ул. Чапаевская, д. 89, г. Самара, 443099, Россия</p></bio><bio xml:lang="en"><p>Yuliya B. Reshetnikova - Head of the Cardiac Imaging Laboratory</p><p>Chapaevskaya St., 89, Samara, 443099, Russia</p></bio><email xlink:type="simple">yu.b.reshetnikova@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Самарский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>05</day><month>09</month><year>2026</year></pub-date><volume>16</volume><issue>3</issue><fpage>161</fpage><lpage>169</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Подсевалов В.С., Гиматдинова Г.Р., Давыдкин И.Л., Данилова О.Е., Решетникова Ю.Б., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Подсевалов В.С., Гиматдинова Г.Р., Давыдкин И.Л., Данилова О.Е., Решетникова Ю.Б.</copyright-holder><copyright-holder xml:lang="en">Podsevalov V.S., Gimatdinova G.R., Davydkin I.L., Danilova O.E., Reshetnikova Y.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnik.reaviz.ru/jour/article/view/1647">https://vestnik.reaviz.ru/jour/article/view/1647</self-uri><abstract><p>Развитие кардиоваскулярной токсичности при высокодозной химиотерапии с аутологичной трансплантацией гемопоэтических стволовых клеток представляет собой осложнение, характеризующееся многообразием клинических проявлений. В статье представлены два клинических случая, которые показывают различные патогенетические варианты кардиоваскулярной токсичности гипотонического типа в раннем посттрансплантационном периоде. В работе рассмотрены пациенты с лимфопролиферативными заболеваниями после двух различных режимов кондиционирования, которые включали высокодозный мелфалан. В первом клиническом случае описан пациент 52 лет с диагнозом множественная миелома, у которого зафиксировано рефрактерное течение гипотензии вследствие сосудистой атонии при сохранной систолической функции левого желудочка и нормальных уровнях кардиоспецифических биомаркеров. Во втором случае у пациентки 46 лет с лимфомой Ходжкина, получавшей ранее терапию антрациклиновыми антибиотиками, после режима кондиционирования по схеме BEAM гипотензия сочеталось со снижением глобальной продольной деформации левого желудочка, повышением тропонина Т и С-реактивного белка, что указывало на комбинированное повреждение миокарда и сосудистого русла. Представленные наблюдения указывают на гетерогенность патогенетических механизмов кардиоваскулярной токсичности гипотонического типа. Рутинная оценка фракции выброса левого желудочка имеет ограниченную ценность в таких случаях. Необходим расширенный мониторинг, который включает дополнение стандартного протокола методикой спекл-трекинга и анализ биомаркеров повреждения миокарда. Это позволяет своевременно диагностировать нарушения и применять дифференцированный подход к лечению.</p></abstract><trans-abstract xml:lang="en"><p>Cardiovascular toxicity following high-dose chemotherapy and autologous hematopoietic stem cell transplantation is a complication characterized by a wide spectrum of clinical manifestations. This article presents two clinical cases that illustrate distinct pathogenetic variants of hypotensive cardiovascular toxicity in the early post-transplant period. The report describes two patients with lymphoproliferative disorders who received different conditioning regimens, both of which included high-dose melphalan. The first case involves a 52-year-old male with multiple myeloma who developed refractory hypotension due to vascular atony, with preserved left ventricular systolic function and normal levels of cardiac-specific biomarkers. In the second case, a 46-year-old female with Hodgkin lymphoma, previously treated with anthracycline antibiotics, received BEAM conditioning and developed hypotension accompanied by a reduction in left ventricular global longitudinal strain, elevated troponin T and C-reactive protein, indicating combined myocardial and vascular injury. These observations highlight the heterogeneous pathogenetic mechanisms underlying hypotensive cardiovascular toxicity. Routine assessment of left ventricular ejection fraction has limited diagnostic value in such settings. Extended monitoring, including speckle-tracking echocardiography and analysis of myocardial injury biomarkers, is warranted to ensure timely diagnosis and a differentiated treatment approach.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>кардиотоксичность</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>трансплантация гемопоэтических стволовых клеток</kwd><kwd>множественная миелома</kwd><kwd>лимфома</kwd><kwd>гипотензия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Cardiotoxicity</kwd><kwd>Endothelial dysfunction</kwd><kwd>Hematopoietic Stem Cell Transplantation</kwd><kwd>Multiple Myeloma</kwd><kwd>Lymphoma</kwd><kwd>Hypotension</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kanegane H, Hoshino A. Inherited lymphoproliferative disorders. Rinsho Ketsueki. 2019;60(6):708-715. https://doi.org/10.11406/rinketsu.60.708 PMID: 31281164</mixed-citation><mixed-citation xml:lang="en">Kanegane H, Hoshino A. Inherited lymphoproliferative disorders. Rinsho Ketsueki. 2019;60(6):708-715. https://doi.org/10.11406/rinketsu.60.708 PMID: 31281164</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ахметзянов Ф.Ш., Ахметзянова Р.Ф., Караманян А.В., Хусаинова Г.Н., Анхимова Л.Е., Горшкова Е.С., и др. К классификации неходжкинских злокачественных лимфом (обзор литературы). Поволжский онкологический вестник. 2023;14(5):69-78. https://doi.org/10.32000/2078-1466-2023-5-69-78</mixed-citation><mixed-citation xml:lang="en">Akhmetzyanov FSh, Akhmetzyanova RF, Karamanyan AV, Khusainova GN, Ankhimova LE, Gorshkova ES, et al. To the classification of non-hodgkin malignant lymphoma (literature review). Oncology Bulletin of the Volga region. 2023;14(5):69-78. (In Russ.). https://doi.org/10.32000/2078-1466-2023-5-69-78</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tavarozzi R, Manzato E, Lombardi A. Lymph Node Ultrasound in Lymphoproliferative Disorders: Where Are We Now? J Clin Imaging Sci. 2021;11:22. https://doi.org/10.25259/JCIS_31_2021 PMID: 33948338</mixed-citation><mixed-citation xml:lang="en">Tavarozzi R, Manzato E, Lombardi A. Lymph Node Ultrasound in Lymphoproliferative Disorders: Where Are We Now? J Clin Imaging Sci. 2021;11:22. https://doi.org/10.25259/JCIS_31_2021 PMID: 33948338</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ibrahim N, Rivera D, Govande J, Mai B. Multiple Myeloma: A Structured and Multidisciplinary Approach to Diagnosis. Semin Diagn Pathol. 2026;43(1):150975. https://doi.org/10.1016/j.semdp.2025.150975 PMID: 41455221</mixed-citation><mixed-citation xml:lang="en">Ibrahim N, Rivera D, Govande J, Mai B. Multiple Myeloma: A Structured and Multidisciplinary Approach to Diagnosis. Semin Diagn Pathol. 2026;43(1):150975. https://doi.org/10.1016/j.semdp.2025.150975 PMID: 41455221</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, et al. Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline. J Clin Oncol. 2026;44(10):914-941. https://doi.org/10.1200/JCO-25-02587 PMID: 41494138</mixed-citation><mixed-citation xml:lang="en">Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, et al. Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline. J Clin Oncol. 2026;44(10):914-941. https://doi.org/10.1200/JCO-25-02587 PMID: 41494138</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто Е.В., Каприн А.Д., Беленков Ю.Н., Васюк Ю.А., Хабарова Н.В., Ильгисонис И.С., и др. Консенсус экспертов Российского кардиологического общества, Общества специалистов по сердечной недостаточности, Ассоциации онкологов России и Ассоциации кардиоонкологов Евразии «Кардиопротекция 2025: современные подходы к профилактике кардиоваскулотоксичности противоопухолевой терапии». Часть I. Введение, цели, методы выявления кардиоваскулотоксичности и стратификация риска. Кардиология. 2025;65(10):4-17. https://doi.org/10.18087/cardio.2025.10.n3076</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, Kaprin AD, Belenkov YuN, Vasyuk YuA, Khabarova NV, Ilgisonis IS. Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiovasculotoxicity in Antitumor Therapy". Part I. Introduction, Objectives, Cardiovasculotoxicity Detection Methods and Risk Stratification. Kardiologiia. 2025;65(10):4-17. (In Russ.). https://doi.org/10.18087/cardio.2025.10.n3076</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Alizadehasl A, Ghadimi N, Hosseinifard H, Roudini K, Emami AH, Ghavamzadeh A, et al. Cardiovascular diseases in patients after hematopoietic stem cell transplantation: systematic review and meta analysis. Curr Res Transl Med. 2023;71(1):103363. https://doi.org/10.1016/j.retram.2022.103363 PMID: 36427416</mixed-citation><mixed-citation xml:lang="en">Alizadehasl A, Ghadimi N, Hosseinifard H, Roudini K, Emami AH, Ghavamzadeh A, et al. Cardiovascular diseases in patients after hematopoietic stem cell transplantation: systematic review and meta analysis. Curr Res Transl Med. 2023;71(1):103363. https://doi.org/10.1016/j.retram.2022.103363 PMID: 36427416</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23. https://doi.org/10.1093/eurheartj/ehac244 PMID: 36017568</mixed-citation><mixed-citation xml:lang="en">Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23. https://doi.org/10.1093/eurheartj/ehac244 PMID: 36017568</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cagnazzo R, Stabile M, Zoppoli G, De Boer RA, Meijers WC, van Der Meer P, et al. Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research. JACC CardioOncol. 2025;7(6):770-773. https://doi.org/10.1016/j.jaccao.2025.05.012 PMID: 40542814</mixed-citation><mixed-citation xml:lang="en">Cagnazzo R, Stabile M, Zoppoli G, De Boer RA, Meijers WC, van Der Meer P, et al. Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research. JACC CardioOncol. 2025;7(6):770-773. https://doi.org/10.1016/j.jaccao.2025.05.012 PMID: 40542814</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Khurshid A, Frishman WH, Aronow WS. Cardiac Complications of Multiple Myeloma Treatments. Cardiol Rev. Published online September 10, 2024. https://doi.org/10.1097/CRD.0000000000000787 PMID: 39254524</mixed-citation><mixed-citation xml:lang="en">Khurshid A, Frishman WH, Aronow WS. Cardiac Complications of Multiple Myeloma Treatments. Cardiol Rev. Published online September 10, 2024. https://doi.org/10.1097/CRD.0000000000000787 PMID: 39254524</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Гиматдинова Г.Р., Данилова О.Е., Давыдкин И.Л., Джулакян У.Л., Усенко Е.В. Диагностические возможности инструментальных методов исследования ранних сердечно-сосудистых нежелательных явлений у больных с лимфопролиферативными заболеваниями, вопросы качества и безопасности. Кардиоваскулярная терапия и профилактика. 2024;23(2):3784. https://doi.org/10.15829/1728-8800-2024-3784</mixed-citation><mixed-citation xml:lang="en">Gimatdinova GR, Danilova OE, Davydkin IL, Dzhulakyan UL, Usenko EV. Diagnostic capabilities of instrumental methods for early cardiovascular adverse events in patients with lymphoproliferative diseases, issues of quality and safety. Cardiovascular Therapy and Prevention. 2024;23(2):3784. (In Russ.). https://doi.org/10.15829/1728-8800-2024-3784</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gong FF, Cascino GJ, Murtagh G, Akhter N. Circulating Biomarkers for Cardiotoxicity Risk Prediction. Curr Treat Options Oncol. 2021;22(6):46. https://doi.org/10.1007/s11864-021-00845-0 PMID: 33866434</mixed-citation><mixed-citation xml:lang="en">Gong FF, Cascino GJ, Murtagh G, Akhter N. Circulating Biomarkers for Cardiotoxicity Risk Prediction. Curr Treat Options Oncol. 2021;22(6):46.  https://doi.org/10.1007/s11864-021-00845-0 PMID: 33866434</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Когония Л.М., Русанов М.О., Шикина В.Е. Кардиотоксичность противоопухолевых препаратов и лучевой терапии у пациентов со злокачественными заболеваниями крови и сóлидными злокачественными новообразованиями. Онкогематология. 2022;17(3):127-136. https://doi.org/10.17650/1818-8346-2022-17-3-127-136</mixed-citation><mixed-citation xml:lang="en">Kogoniya LM, Rusanov MO, Shikina VE. Cardiotoxicity of anticancer drugs and radiation therapy in patients with hematological malignancies and solid malignant neoplasms. Oncohematology. 2022;17(3):127-136. (In Russ.). https://doi.org/10.17650/1818-8346-2022-17-3-127-136</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Гасанов И.И., Темирсултанова Т.Х. Кардиотоксичность противоопухолевой химиотерапии и возможные терапевтические подходы. Медицинский совет. 2025;19(6):201-213. https://doi.org/10.21518/ms2025-141</mixed-citation><mixed-citation xml:lang="en">Gasanov II, Temirsultanova TKh. Cardiotoxicity of anticancer chemotherapy and possible therapeutic approaches. Meditsinskiy sovet. 2025;19(6):201-213. (In Russ.). https://doi.org/10.21518/ms2025-141</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шналиева Н.А., Салогуб Г.Н. Кардиотоксичность ингибиторов протеасом при лечении множественной миеломы: обзор литературы и собственные данные. Российский биомедицинский журнал. 2022;23(1):246-261. https://doi.org/10.18087/2305-7104-2022-23-1-246-261</mixed-citation><mixed-citation xml:lang="en">Shnalieva N.A., Salogub G.N. Cardiotoxicity of proteasome inhibitors in the treatment of multiple myeloma: a review of the literature and our own data. Rossijskiy biomedicinskiy zhurnal. 2022;23(1):246-261. (In Russ.). https://doi.org/10.18087/2305-7104-2022-23-1-246-261</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Галеева З.М., Галявич А.С., Балеева Л.В., Галимзянова Л.А., Якупова Д.Т. Повторные инфаркты миокарда при множественной миеломе. Кардиология. 2021;61(8):87-92. https://doi.org/10.18087/cardio.2021.8.n1237</mixed-citation><mixed-citation xml:lang="en">Galeeva ZM, Galyavich AS, Baleeva LV, Galimzyanova LA, Yakupova DT. Repeated myocardial infarctions in multiple myeloma. Kardiologiia. 2021;61(8):87-92. (In Russ.). https://doi.org/10.18087/cardio.2021.8.n1237</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Фомина Е.В., Карданова С.А., Бочкарникова О.В., Муртузалиев Ш.М., Апполонова С.А., Маркин П.А., и др. Изучение активности системного воспаления и структурно-функционального состояния миокарда, их взаимосвязь у пациентов с множественной миеломой на фоне бортезомибсодержащей противоопухолевой терапии. Кардиология. 2023;63(10):29-38. https://doi.org/10.18087/cardio.2023.10.n2489</mixed-citation><mixed-citation xml:lang="en">Fomina EV, Kardanova SA, Bochkarnikova OV, Murtuzaliev ShM, Appolonova SA, Markin PA, et al. Assessment of systemic inflammation activity, myocardial structure and functional features, their relationship in patients with multiple myeloma, receiving bortezomib therapy. Kardiologiia. 2023;63(10):29-38. (In Russ.). https://doi.org/10.18087/cardio.2023.10.n2489</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jong J, Pinney JR, Packard RRS. Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging. Front Cardiovasc Med. 2022 Aug 3;9:919719. https://doi.org/10.3389/fcvm.2022.919719 PMID: 35990941</mixed-citation><mixed-citation xml:lang="en">Jong J, Pinney JR, Packard RRS. Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging. Front Cardiovasc Med. 2022 Aug 3;9:919719. https://doi.org/10.3389/fcvm.2022.919719 PMID: 35990941</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wu R, Ma L. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Cell Transplant. 2023;32:9636897231179364. https://doi.org/10.1177/09636897231179364 PMID: 37350429</mixed-citation><mixed-citation xml:lang="en">Wu R, Ma L. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Cell Transplant. 2023;32:9636897231179364. https://doi.org/10.1177/09636897231179364 PMID: 37350429</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, et al. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med. 2022;11(3):623. https://doi.org/10.3390/jcm11030623 PMID: 35160072</mixed-citation><mixed-citation xml:lang="en">Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, et al. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med. 2022;11(3):623. https://doi.org/10.3390/jcm11030623 PMID: 35160072</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
